Every 10-Q that GROOVE BOTANICALS INC (GRVE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GRVE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GRVE filings page.
Groove Botanicals, Inc. (GRVE) reported another development-stage quarter with no revenue for the three months ended June 30, 2026. The company posted a net loss of $21,171, improving from a loss of $38,170 a year earlier, and a net loss attributable to common stockholders of $75,789 after $54,618 in preferred dividends. Total operating expenses declined to $28,318, mainly from lower legal and professional fees, and other income of $7,147 came from a settlement with the former audit firm.
The balance sheet remains highly constrained, with total assets of $2,525, current liabilities of $1,546,562, and a stockholders’ deficit of $1,544,037 as of June 30, 2026. This includes $774,140 owed to the CEO for accrued compensation and advances and $710,028 of accrued preferred dividends, while cash was only $1,494. Management states there is substantial doubt about the company’s ability to continue as a going concern and expects to require between $500,000 and $5,000,000 to fund its plans.
The company remains an early-stage vehicle focused on identifying Norwegian-origin technology for potential licensing or commercialization in North America and currently has no products, technologies, or intellectual property rights. Internal controls over financial reporting are deemed ineffective due to a single executive handling key roles and the absence of an independent audit committee. There were 59,643,062 common shares outstanding as of August 10, 2026, and no new equity was issued during the quarter.
Groove Botanicals, Inc. reported another small operating loss with no revenue while pursuing an early-stage EV battery technology strategy. For the nine months ended December 31, 2025, the company recorded a net loss of $104,420, slightly higher than $99,404 a year earlier, and a loss attributable to common stockholders of $268,272.
Total operating expenses were $104,420, driven mainly by general and administrative, legal, rent and consulting costs. The company continues to pay substantial preferred dividends of about $163,852 for the nine-month period, which deepen losses available to common holders.
Liquidity is very constrained. As of December 31, 2025, cash was only $1,494 and total assets were $6,260, against current liabilities of $1,384,394, including related party payables of $719,961 and significant dividends payable on preferred stock. Stockholders’ deficit was $1,378,134. The company discloses substantial doubt about its ability to continue as a going concern and is relying on related-party financing while seeking $500,000 to $5,000,000 of new capital.
Groove Botanicals, Inc. (GRVE) reported another development-stage quarter with no revenue and continued losses as it pursues an EV battery technology strategy. For the six months ended September 30, 2025, the company recorded a net loss of $70,553 before preferred dividends, slightly higher than the $66,372 loss a year earlier. After preferred dividends of $109,235, the net loss attributable to common stockholders was $179,788.
Liquidity remains extremely tight, with $1,492 of cash and total assets of $8,164 against current liabilities of $1,297,813, resulting in a stockholders’ deficit of $(1,289,649) as of September 30, 2025. Operations are being funded largely through related-party advances, which totaled $55,124 of cash inflows in the six-month period, while related party payables reached $687,957.
The company has incurred cumulative losses of $35,376,369 and discloses that these factors raise substantial doubt about its ability to continue as a going concern. It has no products or patents yet, plans to acquire early-stage EV battery technologies in Scandinavia, and estimates future capital needs between $500,000 and $5,000,000, with no committed financing in place.